| Literature DB >> 35741181 |
Federica Veronese1, Vanessa Tarantino1, Elisa Zavattaro2, Francesca Biacchi3, Chiara Airoldi2, Massimo Salvi4, Silvia Seoni4, Francesco Branciforti4, Kristen M Meiburger4, Paola Savoia5.
Abstract
Background: Due to the COVID-19 pandemic, teledermoscopy has been increasingly used in the remote diagnosis of skin cancers. In a study conducted in 2020, we demonstrated a potential role of an inexpensive device (NurugoTM Derma) as a first triage to select the skin lesions that require a face-to-face consultation with dermatologists. Herein, we report the results of a novel study that aimed to better investigate the performance of NurugoTM.Entities:
Keywords: skin cancer diagnosis; teledermatology; teledermoscopy
Year: 2022 PMID: 35741181 PMCID: PMC9221805 DOI: 10.3390/diagnostics12061371
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1(Top) Representation of the portable dermatoscope connected to the camera (A,B) and of the NurugoTM Derma (G) connected to the smartphone (H,I); (Bottom) Examples of images acquired with the different devices and image pre-processing (Dermatoscope from (C–F); NurugoTM Derma from (J–L)).
Figure 2Examples of images to be evaluated through the REDCap software; (A) Table of the instruments in use. The images were acquired with instrument N (B), F (C) and V (D,E).
Results of the descriptive analysis separated for the three different instruments and for the four dermatologists. Absolute and % values are reported. Instrument F: dermatoscope; Instrument N: Nurugo; Instrument V: Nurugo in epiluminescence setting with slide; C: real clinical condition.
| Dermatologist 1 | Dermatologist 2 | Dermatologist 3 | Dermatologist 4 | Real Clinical Diagnosis C | |
|---|---|---|---|---|---|
|
| |||||
| Instrument F | |||||
| Nevus | 85 (59.03%) | 64 (44.44%) | 73 (50.69%) | 72 (50%) | 75 (52.08%) |
| Melanoma | 10 (6.94%) | 18 (12.5%) | 9 (6.25%) | 3 (2.08%) | |
| Seborrheic keratoses | 29 (20.14%) | 39 (27.08%) | 44 (30.56%) | 41 (28.47%) | 36 (25.00%) |
| Basal cell carcinoma | 20 (13.89%) | 23 (15.97%) | 18 (12.5%) | 28 (19.44%) | 27 (18.75%) |
| Instrument N | |||||
| Nevus | 72 (50%) | 68 (47.22%) | 61 (42.36%) | 46 (31.94%) | |
| Melanoma | |||||
| Seborrheic keratoses | 36 (25%) | 35 (24.31%) | 36 (25%) | 57 (39.58%) | |
| Basal cell carcinoma | 29 (20.14%) | 25 (17.36%) | 23 (15.97%) | 38 (26.39%) | |
| Instrument V | |||||
| Nevus | 76 (52.78%) | 52 (36.11%) | 70 (48.61%) | ||
| Melanoma | |||||
| Seborrheic keratoses | 23 (15.97%) | 44 (30.56%) | 29 (20.14%) | ||
| Basal cell carcinoma | 28 (19.44%) | 19 (13.19%) | 25 (17.36%) | 34 (23.61%) | |
|
| |||||
| Instrument F | |||||
| SI | 30 (20.83%) | 31 (21.53%) | 44 (30.56%) | 48 (33.33%) | |
| Instrument N | |||||
| SI | 36 (25.00%) | 75 (52.08%) | 57 (39.58%) | ||
| Instrument V | |||||
| SI | 50 (34.72%) | 79 (54.86%) | 48 (33.33%) |
Cohen’s K values with respective 95% CI.
| Dermatologist 1 | Dermatologist 2 | Dermatologist 3 | Dermatologist 4 | |
|---|---|---|---|---|
|
| ||||
| F vs. C | 0.64 [0.53–0.75] | 0.80 [0.72–0.88] | 0.70 [0.60–0.80] | 0.85 [0.77–0.92] |
| N vs. C | 0.75 [0.66–0.84] | 0.78 [0.69–0.86] | 0.62 [0.51–0.71] | 0.59 [0.49–0.69] |
| V vs. C | 0.65 [0.55–0.75] | 0.60 [0.51–0.70] | 0.66 [0.56–0.76] | 0.53 [0.42–0.64] |
|
| ||||
| F vs. C | 0.69 [0.56–0.82] | 0.79 [0.69–0.89] | 0.67 [0.54–0.80] | 0.87 [0.79–0.96] |
| N vs. C | 0.63 [0.50–0.77] | 0.42 [0.29–0.55] | 0.38 [0.24–0.52] | 0.57 [0.43–0.71] |
| V vs. C | 0.60 [0.46–0.74] |
| 0.50 [0.38–0.63] | 0.63 [0.49–0.76] |
Part A. Percentage agreement (%). Part B. Absolute number and relative percentage of “serious diagnostic errors”.
| Part A | Dermatologist 1 | Dermatologist 2 | Dermatologist 3 | Dermatologist 4 |
|---|---|---|---|---|
|
| ||||
| F vs. C | 77.78% | 86.81% | 81.25% | 90.28% |
| N vs. C | 84.03% | 85.42% | 73.61% | 72.22% |
| V vs. C | 77.78% | 72.22% | 77.78% | 67.36% |
|
| ||||
| F vs. C | 87.50% | 90.28% | 86.81% | 94.44% |
| N vs. C | 84.72% | 69.44% | 68.75% | 79.86% |
| V vs. C | 81.94% | 64.58% | 74.31% | 83.33% |
|
| Dermatologist 1 | Dermatologist 2 | Dermatologist 3 | Dermatologist 4 |
|
| ||||
| F vs. C | 8 (24.24%) | 3 (9.09%) | 9 (27.27%) | 4 (12.12%) |
| N vs. C | 6 (18.28%) | 3 (9.09%) | 5 (15.15%) | 8 (24.24%) |
| V vs. C | 2 (6.06%) | 4 (12.12%) | 2 (6.06%) | 3 (9.09%) |